Stock SRRK SCHOLAR ROCK HOLDING CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Scholar Rock Holding Corporation

Equities

SRRK

US80706P1030

Real-time Estimate Cboe BZX
Other stock markets
 18:21:49 27/06/2024 BST 		5-day change 1st Jan Change
8.11 USD +3.44% Intraday chart for Scholar Rock Holding Corporation -3.86% -57.55%
06-24 Scholar Rock Holding Corporation Announces New SRK-439 Preclinical Data Showing Significant Lean Mass Preservation and Attenuation of Fat Mass Rebound Following GLP-1 Receptor Agonist Withdrawal CI
06-13 BMO Capital Raises Price Target on Scholar Rock to $31 From $29, Maintains Outperform Rating MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Scholar Rock Holding Corporation Announces New SRK-439 Preclinical Data Showing Significant Lean Mass Preservation and Attenuation of Fat Mass Rebound Following GLP-1 Receptor Agonist Withdrawal
Scholar Rock Reports 'Encouraging' Phase 1 Trial Results in Advanced Solid Tumors
Scholar Rock to Present New Data from SRK-181 Phase 1 DRAGON Trial at the American Society of Clinical Oncology Annual Meeting
Scholar Rock Starts Phase 2 Trial of Apitegromab in Obesity
Scholar Rock Holding Corporation Announces Initiation of Phase 2 EMBRAZE Trial of Apitegromab in Obesity and New Preclinical Data Supporting SRK-439 in Obesity
Scholar Rock Shares Fall on Wider-Than-Expected Q1 Loss
Scholar Rock Holding Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024
Scholar Rock Shares Rise After Raymond James Initiates Coverage
Scholar Rock Holding Corporation Reports Earnings Results for the Full Year Ended December 31, 2023
Scholar Rock Holding Corporation Reports Earnings Results for the Full Year Ended December 31, 2023
Scholar Rock Announces Management Appointments
Scholar Rock Presents New Preclinical Data Demonstrating Potential Benefit of SRK-439 for Healthy Weight Loss Management
Scholar Rock Announces FDA Clearance of IND Application to Initiate Phase 2 Proof-of-Concept Trial with Apitegromab to Treat Obesity
Adipositas-Mittel führen zu Muskelverlust - Pharmafirmen steuern gegen
Scholar Rock Holding Insider Sold Shares Worth $448,444, According to a Recent SEC Filing
Scholar Rock Holding Insider Sold Shares Worth $436,820, According to a Recent SEC Filing
Scholar Rock Holding Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Scholar Rock Holding Insider Sold Shares Worth $438,039, According to a Recent SEC Filing
Scholar Rock's Experimental Drug Shows Anti-Tumor Activity in Early-Stage Trial
Scholar Rock, Inc. Presents New Data from Phase 1 Dragon Trial Showing Promising Anti-Tumor Activity in Anti-Pd-1 Resistant Metastaticcc Patients and Supporting Srk-181 Continued Tolerability
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SRRK Stock
  4. News Scholar Rock Holding Corporation
  5. Other languages